Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Trexquant Investment LP

Trexquant Investment LP reduced its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 21.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,217 shares of the company’s stock after selling 76,491 shares during the quarter. Trexquant Investment LP owned about 0.36% of Travere Therapeutics worth $4,881,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TVTX. R Squared Ltd purchased a new position in shares of Travere Therapeutics during the fourth quarter worth about $53,000. Quarry LP purchased a new position in Travere Therapeutics during the 3rd quarter worth approximately $105,000. Victory Capital Management Inc. purchased a new position in Travere Therapeutics during the 4th quarter worth approximately $182,000. Baader Bank Aktiengesellschaft acquired a new position in Travere Therapeutics during the fourth quarter worth approximately $192,000. Finally, Entropy Technologies LP purchased a new stake in Travere Therapeutics in the fourth quarter valued at approximately $214,000.

Travere Therapeutics Trading Down 9.5 %

Shares of Travere Therapeutics stock opened at $14.99 on Friday. The company has a 50-day moving average of $20.48 and a two-hundred day moving average of $18.61. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock has a market cap of $1.33 billion, a PE ratio of -3.66 and a beta of 0.84.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The firm had revenue of $74.79 million during the quarter, compared to analysts’ expectations of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. On average, research analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Insider Buying and Selling

In other Travere Therapeutics news, CAO Sandra Calvin sold 54,244 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the sale, the chief accounting officer now owns 54,410 shares of the company’s stock, valued at $1,360,250. This represents a 49.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP William E. Rote sold 2,437 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the sale, the senior vice president now owns 83,170 shares in the company, valued at $1,618,488.20. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 189,269 shares of company stock worth $4,155,251 in the last three months. Corporate insiders own 3.75% of the company’s stock.

Analyst Ratings Changes

TVTX has been the topic of several research reports. Bank of America raised their price objective on shares of Travere Therapeutics from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st. JPMorgan Chase & Co. boosted their price target on Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. HC Wainwright increased their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Evercore ISI boosted their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Scotiabank increased their price target on Travere Therapeutics from $27.00 to $32.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $31.46.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.